Annual report pursuant to Section 13 and 15(d)

SEGMENT INFORMATION (Tables)

v3.20.1
SEGMENT INFORMATION (Tables)
 12 Months Ended
Dec. 31, 2019
Segment Reporting [Abstract]  
Schedule Of Segment Reporting Information
The following table presents information by reportable operating segment for the years ended December 31, 2019 and 2018 (in thousands):
 
Consumer Products
Segment
 
Specialty Pharmaceutical Segment
 
Consolidated Totals
Year ended December 31, 2019:
 

 
 

 
 

Product sales, net
$
53,696

 
$
—

 
$
53,696

 
 
 
 
 
 
Gross profit
$
35,088

 
$
—

 
$
35,088

Research and development
2,106

 
3,771

 
5,877

Selling, general and administrative
46,405

 
46

 
46,451

Operating loss
$
(13,423
)
 
$
(3,817
)
 
$
(17,240
)
 
 
 
 
 
 
Year ended December 31, 2018:
 
 
 
 
 
Product sales, net
$
48,244

 
$
—

 
$
48,244

 
 
 
 
 
 
Gross profit
$
33,878

 
$
—

 
$
33,878

Research and development
1,008

 
877

 
1,885

Selling, general and administrative
21,697

 
49

 
21,746

Operating income (loss)
$
11,173

 
$
(926
)
 
$
10,247